Skip to content
A Green Sign – Lifestyle
Author:
UroGen Pharma Ltd.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 5, 2026
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
June 1, 2026
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
May 15, 2026
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
May 13, 2026
UroGen Pharma to Present at Upcoming Investor Conferences
May 7, 2026
←
Previous Page
1
2